The predictive value of early molecular response by relative risk in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with dasatinib (DAS) or imatinib (IM) from the phase 3 DASISION trial

被引：0
|
作者：
Stegelmann, F. [1 ]
Shah, N. P. [2 ]
Saglio, G. [3 ]
Hochhaus, A. [4 ]
Bilmes, R. [5 ]
Li, L. [5 ]
Cortes, J. E. [6 ]
机构：
[1] Univ Klinikum Ulm, Ulm, Germany
[2] UCSF, Sch Med, San Francisco, CA USA
[3] Univ Turin, Turin, Italy
[4] Univ Klinikum Jena, Jena, Germany
[5] Bristol Myers Squibb, Princeton, NJ USA
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V158
引用
收藏
页码：40 / 40
页数：1
相关论文
共 50 条
  • [1] Early molecular response in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with dasatinib (DAS) or imatinib (IM) from DASISION.
    Shah, Neil P.
    Saglio, Giuseppe
    Hochhaus, Andreas
    Bilmes, Robyn
    Li, Li
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] THE IMPACT OF EARLY MOLECULAR RESPONSE ON LONG-TERM OUTCOMES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) TREATED WITH DASATINIB OR IMATINIB FROM THE DASISION TRIAL
    Stegelmann, F.
    Shah, N. P.
    Saglio, G.
    Hochhaus, A.
    Bilmes, R.
    Li, L.
    Cortes, J. E.
    HAEMATOLOGICA, 2016, 101 : 240 - 240
  • [3] Phase II trial of dasatinib (DAS) in pediatric patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP).
    Gore, Lia
    Kearns, Pamela
    Lee, Maria Lucia
    De Souza, Carmino Antonio
    Bertrand, Yves
    Hijiya, Nobuko
    Stork, Linda C.
    Chung, Nack-Gyun
    Cardenas-Cardos, Rocio
    Saikia, Tapan
    Fagioli, Franca
    Seo, Jong-Jin
    Landman-Parker, Judith
    Lancaster, Donna
    Place, Andrew E.
    Rabin, Karen R.
    Sacchi, Mariana
    Swanink, Rene
    Zwaan, Michel
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] Safety and Efficacy of Dasatinib (DAS) Vs. Imatinib (IM) by Baseline Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial
    Khoury, H. Jean
    Cortes, Jurge E.
    Kantarjian, Hagop
    Baccarani, Michele
    Shah, Neil P.
    Bradley-Garelik, M. Brigid
    Dejardin, David
    Hochhaus, Andreas
    BLOOD, 2010, 116 (21) : 1401 - 1401
  • [5] EFFICACY AND SAFETY OF DASATINIB VS IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): EUROPEAN SUBPOPULATION ANALYSIS OF THE PHASE 3 DASISION TRIAL
    Mayer, J.
    Warzocha, K.
    Huguet, F.
    Stegelmann, F.
    Steegmann, J.
    Gambacorti-Passerini, C.
    Lofgren, C.
    Dejardin, D.
    Hochhaus, A.
    HAEMATOLOGICA, 2012, 97 : 75 - 75
  • [6] Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up.
    Hochhaus, Andreas
    Shah, Neil P.
    Cortes, Jorge E.
    Baccarani, Michele
    Bradley-Garelik, M. Brigid
    Dejardin, David
    Kantarjian, Hagop
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Two-year follow-up from DASISION
    Kantarjian, H.
    Shah, N. P.
    Cortes, J. E.
    Baccarani, M.
    Bradley-Garelik, M. B.
    Zhu, C.
    Hochhaus, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Efficacy and Safety Outcomes by Baseline Comorbidity and Age in Patients Newly Diagnosed with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Treated with Dasatinib or Imatinib in DASISION
    Mauro, Michael J.
    Cortes, Jorge E.
    Hochhaus, Andreas
    Shah, Neil P.
    Atallah, Ehab
    Abaskharoun, Mena
    Sy, Oumar
    Saglio, Giuseppe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : S14 - S15
  • [9] Dasatinib vs imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): DASISION European subpopulation analysis
    Stegelmann, F.
    Mayer, J.
    Warzocha, K.
    Huguet, F.
    Steegmann, J. L.
    Gambacorti-Passerini, C.
    Lofgren, C.
    Dejardin, D.
    Hochhaus, A.
    ONKOLOGIE, 2012, 35 : 47 - 48
  • [10] Dasatinib (Versus Imatinib) In Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of Safety and Efficacy by Use of Baseline Medications In the DASISION Trial.
    Guilhot, Francois
    Kantarjian, Hagop
    Shah, Neil P.
    Hochhaus, Andreas
    Bradley-Garelik, M. Brigid
    Dejardin, David
    Cortes, Jorge E.
    BLOOD, 2010, 116 (21) : 946 - 947
12345